Surrogate endpoints in trials-a call for better reporting

被引：5
|
作者：
Ciani, Oriana [1 ]
Manyara, Anthony M. [2 ]
Taylor, Rod S. [2 ,3 ]
机构：
[1] SDA Bocconi Sch Management, Milan, Italy
[2] Univ Glasgow, Inst Hlth & Wellbeing, MRC CSO Social & Publ Hlth Sci Unit, Glasgow, Lanark, Scotland
[3] Univ Glasgow, Inst Hlth & Wellbeing, Robertson Ctr Biostat, Glasgow, Lanark, Scotland
来源：
BMJ-BRITISH MEDICAL JOURNAL | 2022年 / 378卷
基金：
英国医学研究理事会;
关键词：
CLINICAL-TRIALS; PROTOCOL; STANDARD;
D O I：
10.1136/bmj.o1912
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [41] The use of surrogate endpoints in clinical trials: focus on clinical trials in cardiovascular diseases
    Lonn, E
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2001, 10 (06) : 497 - 508
  • [42] Use of surrogate endpoints vs. clinical outcome trials for registration trials
    Calvo, G.
    Suarez, M. L.
    Ruiz, M.
    PROCEEDINGS OF THE 8TH CONGRESS OF THE EUROPEAN ASSOCIATION FOR CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2007, : 5 - +
  • [43] Misuse and Reporting of Renal Endpoints in Randomized Clinical Trials
    Halimi, Jean-Michel
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2012, 59 (01) : 160 - 160
  • [44] MAJOR CARDIOVASCULAR TRIALS WITH PRIMARY SURROGATE ENDPOINTS: 2006 TO 2011
    Bikdeli, Behnood
    Punnanithinont, Natdanai
    Shi, Ruizhi
    Ross, Joseph
    Krumholz, Harlan
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2013, 61 (10) : E1585 - E1585
  • [45] Defining Surrogate Endpoints for Clinical Trials in Severe Falciparum Malaria
    Jeeyapant, Atthanee
    Kingston, Hugh W.
    Plewes, Katherine
    Maude, Richard J.
    Hanson, Josh
    Herdman, M. Trent
    Leopold, Stije J.
    Ngernseng, Thatsanun
    Charunwatthanal', Prakaykaew
    Nguyen Hoan Phu
    Ghose, Aniruddha
    Hasan, M. Mahtab Uddin
    Fanello, Caterina I.
    Faiz, Md Abul
    Tran Tinh Hien
    Day, Nicholas P. J.
    White, Nicholas J.
    Dondorp, Arjen M.
    PLOS ONE, 2017, 12 (01):
  • [46] Trends in Utilization of Surrogate Endpoints in Contemporary Cardiovascular Clinical Trials
    Patel, Ravi B.
    Vaduganathan, Muthiah
    Samman-Tahhan, Ayman
    Kalogeropoulos, Andreas P.
    Georgiopoulou, Vasiliki V.
    Fonarow, Gregg C.
    Gheorghiade, Mihai
    Butler, Javed
    AMERICAN JOURNAL OF CARDIOLOGY, 2016, 117 (11): : 1845 - 1850
  • [47] Surrogate and Intermediate Endpoints in Randomized Trials: What's the Goal?
    Korn, Edward L.
    Freidlin, Boris
    CLINICAL CANCER RESEARCH, 2018, 24 (10) : 2239 - 2240
  • [48] Trials for Slowly Progressive Neurogenetic Diseases Need Surrogate Endpoints
    Reilly, Mary M.
    Herrmann, David N.
    Pareyson, Davide
    Scherer, Steven S.
    Finkel, Richard S.
    Zuechner, Stephan
    Burns, Joshua
    Shy, Michael E.
    ANNALS OF NEUROLOGY, 2023, 93 (05) : 906 - 910
  • [49] SURROGATE ENDPOINTS IN CLINICAL-TRIALS - DEFINITION AND OPERATIONAL CRITERIA
    PRENTICE, RL
    STATISTICS IN MEDICINE, 1989, 8 (04) : 431 - 440
  • [50] SURROGATE ENDPOINTS AS PREDICTORS OF SURVIVAL IN METASTATIC UROTHELIAL CANCER TRIALS
    Ghali, Fady
    Patel, Devin
    Jewell, Teresa
    Gore, John
    Wright, Jonathan
    JOURNAL OF UROLOGY, 2022, 207 (05): : E980 - E980
12345